In summary, the potential to overcome P. falciparum resistance
to CQ both in vitro and in vivo has been demonstrated using a hybrid
design strategy, which conjugated the antiplasmodial agents,
chloroquine and astemizole, into a single molecule. Further work
in this area should focus on improving the drug-like properties of
the hybrid agents, which may in turn improve the in vivo efficacy
of this class of compounds.